<SEC-DOCUMENT>0001387131-18-001522.txt : 20180411
<SEC-HEADER>0001387131-18-001522.hdr.sgml : 20180411
<ACCEPTANCE-DATETIME>20180411060301
ACCESSION NUMBER:		0001387131-18-001522
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180411
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180411
DATE AS OF CHANGE:		20180411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		18749090

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_041118.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 20%; margin-top: 0; margin-bottom: 0">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">FORM 8-K</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">SECURITIES EXCHANGE
ACT OF 1934<BR>
</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
April 11, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 16pt"><B>TherapeuticsMD,
    Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant's telephone number, including area
code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 11, 2018, TherapeuticsMD,
Inc., a Nevada corporation (the &ldquo;Company&rdquo;), issued a press release announcing that the Company had entered into negotiations
with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) regarding the proposed label for TX-004HR, the Company's investigational
applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse
(dyspareunia), a symptom of vulvar and vaginal atrophy (&ldquo;VVA&rdquo;) due to menopause. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information in Items
7.01 and 9.01 of this Current Report on Form 8-K (including the exhibit) is furnished and shall not be deemed to be &ldquo;filed&rdquo;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise
subject to the liabilities of that section. The information in Items 7.01 and 9.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 9.01.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: right"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Exhibits.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1.5in"><FONT STYLE="font-size: 10pt">Exhibit</FONT><BR>
<FONT STYLE="font-size: 10pt"><U>Number</U></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ex99-1.htm">Press Release from TherapeuticsMD, Inc., dated April 11, 2018, entitled &ldquo;TherapeuticsMD Enters Into Label Negotiations for TX-004HR.&rdquo;</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="letter-spacing: -0.1pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;April 11, 2018</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-8k_041118.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 4pt 0 0 314pt; text-align: right"><IMG SRC="cgo-cover_img001.gif" ALT="" STYLE="height: 31px; width: 270px"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05in 88.9pt 0 0">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.3pt; text-align: center"><B>TherapeuticsMD Enters Into Label Negotiations
for TX-004HR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.3pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BOCA
RATON, Florida, April 11, 2018</B> &#8211; TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women&#8217;s
healthcare company, today announced that the Company has entered into negotiations with the U.S. Food and Drug Administration (FDA)
regarding the proposed label for TX-004HR, the Company&#8217;s investigational applicator-free estradiol vaginal softgel capsule
for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy
(VVA) due to menopause. As previously announced, the Prescription Drug User Fee Act (PDUFA) target action date for the completion
of the FDA&#8217;s review of the new drug application (NDA) for TX-004HR is May 29, 2018. The Company does not anticipate providing
subsequent updates with respect to label negotiations prior to the PDUFA target action date. There can be no assurance that the
FDA will approve the NDA for TX-004HR, or that such approval will occur by the PDUFA target action date, and the entrance into
label negotiations does not imply otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc. is an innovative healthcare
company focused on developing and commercializing products exclusively for women. With its SYMBODA&#8482; technology, TherapeuticsMD
is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of
dosage forms and administration routes. The Company&#8217;s late stage clinical pipeline includes two product candidates that have
completed phase 3 trials and are awaiting approval by the FDA: TX-001HR for treatment of moderate-to-severe vasomotor symptoms
(VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a
symptom of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and generic
prescription prenatal vitamins under the vitaMedMD&reg; and BocaGreenMD&reg; brands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release by TherapeuticsMD, Inc.
may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to
TherapeuticsMD&#8217;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221;
&#8220;should,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions and are based on assumptions and
assessments made in light of management&#8217;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&#8217;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &#8220;Risk Factors&#8221; in the company&#8217;s filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
the company&#8217;s ability to resolve the deficiencies identified by the FDA in the company&#8217;s new drug application for its
TX-004HR product candidate and the time frame associated with such resolution; whether the FDA will approve the amended NDA for
the company&#8217;s TX-004HR product candidate and whether such approval will occur by the PDUFA target action date; whether the
FDA will approve the NDA for the company&#8217;s TX-001HR product candidate and whether such approval will occur by the PDUFA target
action date; the company&#8217;s ability to maintain or increase sales of its products; the company&#8217;s ability to develop
and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and
uncertain results of the company&#8217;s clinical trials, including any additional clinical trials that the FDA may require in
connection with TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of the company&#8217;s
hormone therapy drug candidates; the company&#8217;s reliance on third parties to conduct its clinical trials, research and development
and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company&#8217;s
products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility
of the trading price of the company&#8217;s common stock and the concentration of power in its stock ownership. PDF copies of the
company&#8217;s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt"><B><U>Investor Contact</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0">David DeLucia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0">Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">561-961-1900<BR>
David.DeLucia@TherapeuticsMD.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cgo-cover_img001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgo-cover_img001.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M.6R$&D+A99?&66G @1Y"H(R(UAL"#J1,)KD-1$PF/PBHB29OC)A&C :]:.)
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M-,?NA6^*?%(7879#R7YQQ59(\L&KU,=$3_[0@1T<YKZR8C1&/JX@UA-081X
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EXR /N<@GDLP-COSD*!5/N4%6IO*6N_SE,(^YS&=.\YH_)"  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
